
News|Articles|October 21, 2025
The Fellow's Playbook: How to Make the Most of Your First Oncology Meeting
Author(s)Ariana Pelosci
Fact checked by: Russ Conroy
Third-year fellows from Weill Cornell Medicine offer 7 key tips for establishing a foundational understanding of the field at major oncology meetings.
Advertisement
Advertisement
Attending a major oncology conference such as the American Society of Clinical Oncology (ASCO) Annual Meeting or the American Society of Hematology Annual Meeting & Exposition for the first time as a fellow can be exhilarating and overwhelming. The sheer volume of groundbreaking data, the simultaneous sessions, and the hundreds of thought leaders can make a new trainee feel a little insignificant.
Related to this article

National registry data show 5-year overall survival in children and adolescents with cancer rose from 60% in 1975 to 90% in 2017.

The FDA approved the PCR-based OncoMate MSI Dx Analysis System to identify patients with microsatellite instability–high solid tumors who may be eligible for pembrolizumab.

In OptimUM-01, darovasertib plus crizotinib produced a 34.1% ORR and 21.1-month median OS in untreated metastatic uveal melanoma, regardless of HLA status.

Qingqing Cai, MD, PhD, discussed early efficacy data for rocbrutinib plus R-CHOP in untreated non-GCB DLBCL and how they compare with frontMIND at ESMO 2026.

The CHMP recommended belzutifan plus lenvatinib for advanced clear cell RCC after anti–PD-(L)1 therapy, based on phase 3 LITESPARK-011 data.

Adjuvant cretostimogene reduced recurrence risk by 68% vs surveillance in intermediate-risk and high-grade Ta NMIBC in the phase 3 PIVOT-006 trial.

The FDA has approved pertuzumab-qcay, a biosimilar of the reference product Perjeta, in HER2-positive breast cancer, based on a data package that showed no meaningful differences in quality, safety, efficacy, or immunogenicity.
Advertisement
Advertisement

